Table 1.
Summary of studies on IPL for DED Therapy
| Year | Design | Patients (n) | IPL sessions (n) | Dry eye symptom | BUT | Meibomian function | Reference |
|---|---|---|---|---|---|---|---|
| 2020 | Prospective randomised double-masked placebo-controlled | 58 | 5 | Improved OSDI, SPEED, SANDE | Improved | Improved | 41 |
| 2020 | Prospective randomized double-masked sham-controlled | 114 | 3 | Improved OSDI | Improved | Improved | 62 |
| 2020 | Prospective controlled randomized |
29 | 3 | Improved OSDI | Improved | Improved | 32 |
| 2020 | Retrospective | 43 | Mild group: 2; Moderate group: 3;Severe group: 4 | Improved OSDI in mild and moderate atrophy patients, not severe ones | Improved in mild and moderate atrophy patients, not in severe ones | Improved in mild and moderate atrophy patients, not in severe ones | 45 |
| 2019 | Prospective controlled randomized |
45 | 3 | Improved SPEED | Improved | Improved | 60 |
| 2019 | Prospective controlled randomized |
45 | 8 | Improved SPEED | Improved | Improved | 43 |
| 2019 | Prospective controlled | 12 | 1 | Improved OSDI | Improved | - | 66 |
| 2019 | Prospective comparative | 40 | 3 | Improved OSDI | Improved | - | 63 |
| 2019 | Prospective noncomparative | 30 | 3 | Improved OSDI | Improved | Improved | 56 |
| 2019 | Prospective noncomparative | 19 | 3 | Subjective symptoms improved |
Improved | No statistically significant changed | 48 |
| 2019 | Prospective noncomparative | 30 | 3 | Improved OSDI | Improved | Improved | 76 |
| 2019 | Case-control | 82 | 1 | Improved OSDI | Improved | Improved | 70 |
| 2019 | Retrospective | 28 | 3 | Subjective symptoms improved | Improved | Improved | 49 |
| 2019 | Retrospective | 25 | - | Improved OSDI | Improved | Improved | 22 |
| 2018 | Prospective, randomized, double-masked, controlled | 44 | 3 | Improved SPEED | Improved | Improved | 59 |
| 2018 | Prospective controlled randomized | 28 | 3 | Improved SPEED | Improved | Improved | 57 |
| 2018 | Prospective noncomparative | 31 | 4-8 | Improved SPEED | Improved | Improved | 44 |
| 2018 | Prospective noncomparative | 26 | 3 | Subjective symptoms improved | Improved | - | 68 |
| 2018 | Prospective noncomparative non-randomized |
17 | 4 | Improved OSDI | Improved | Improved | 69 |
| 2018 | Prospective Cohort | 35 | 3 | Improved OSDI | Improved | Improved | 72 |
| 2017 | Prospective, randomized, double-masked, controlled | 44 | 3 | Improved OSDI, SPEED | Improved | Improved | 67 |
| 2017 | Prospective, randomized, double-masked, controlled | 44 | 3 | Improved SPEED with no statistical difference | Improved | Improved | 74 |
| 2017 | Prospective interventional noncomparative |
40 | 4 | Improved SPEED | Improved | Improved | 50 |
| 2017 | Prospective noncomparative | 36 | 4 | - | Improved | - | 47 |
| 2016 | Prospective, open label | 40 | 4 | Subjective symptoms improved | Improved | Improved | 75 |
| 2016 | Retrospective | 100 | 4 | Improved OSDI | Improved | Improved | 61 |
| 2015 | Prospective controlled | 28 | 3 | Improved OSDI, SPEED | Improved | - | 37 |
| 2015 | Retrospective noncomparative case series | 91 | 7 | Subjective symptoms improved | Improved | - | 3 |